Bayer supports rebuilding of Ukrainian healthcare system by donating 1.3 million euros
Financial support for the Chernihiv Medical Center of Modern Oncology and the Romodanov Institute of Neurosurgery / The donation goes to UNITED24, the main platform for charitable donations to reconstruct Ukraine
Leverkusen, November 29, 2022 – Bayer supports rebuilding of the Ukrainian healthcare system with a donation of 1.3 million euros to the UNITED24 fundraising platform. UNITED24 was launched in May 2022 by the President of Ukraine, Volodymyr Zelensky, as the primary platform for charitable donations to reconstruct Ukraine.
The donated amount will support two projects equally. Bayer will provide financial aid to restore the infrastructure of the Chernihiv Medical Center of Modern Oncology. Their valuable equipment and facilities were significantly damaged due to Russian artillery shelling. Currently, the main building needs considerable repairs, requiring about 650,000 euros of investment. The company is making another donation of 650,000 euros to the Romodanov Institute of Neurosurgery. The donation will help the Institute purchase medical equipment for high-tech neurosurgical interventions and support complete patient rehabilitation.
“The rebuilding of the national health system in Ukraine is of utmost importance. It will be fundamental to ensuring access to medical relief and appropriate treatment. In addition to our ongoing support for the Ukrainian agricultural system, our new donation will have a positive impact on the lives of the Ukrainian people”, says Bayer CEO Werner Baumann.
“Medical equipment for the Neurological Institute in Kyiv and rebuilding of the infrastructure of the Oncology Center in Chernihiv will help patients to receive high quality medical treatment and contribute to their rehabilitation. We want to support Ukraine and the Ukrainian patients in these challenging times”, says Oliver Gierlichs, General Director of Bayer Ukraine.
Bayer is committed to Ukraine’s future
Beyond this donation, Bayer is fully committed to investing in Ukraine and supporting President Zelensky’s rebuilding plan. The company aims to continue making significant investments in the country over the next decade – mainly to rebuild Ukraine´s agricultural system. As part of its humanitarian relief, the company has donated more than 10 million euros in monetary and product donations. This includes establishing a disaster relief fund and in-kind donations, including antibiotics, hematology, and oncology therapeutics, as well as agricultural inputs.
In addition, the company is partnering with the U.S. Agency for International Development (USAID), through the Agriculture Resilience Initiative Ukraine (AGRI-Ukraine), to address the immediate and longer-term demand for corn seed among Ukrainian farmers and other countries that depend on seed from Ukraine. Bayer has committed to investing 35 million euros from 2022 onwards in the Pochuiky seed plant. This investment includes increasing the capacity of seeds dryer, providing extra field equipment and additional storage facilities, and will lead to new employment opportunities in the region.
Bayer’s humanitarian support to Ukraine is summarized here: bayer.com/en/ukraine
About the State Institution Romodanov Neurosurgery Institute National Academy of Medical Sciences of Ukraine
The Romodanov Institute of Neurosurgery is a leading neurosurgery institution in Ukraine that provides specialized high-tech care to thousands of patients. Currently, 30 percent of all hospitalized patients at the Institute are victims of the war in Ukraine. Most injured people with craniocerebral and vertebral-spinal cord injuries are hospitalized in serious or extremely serious conditions and require rehabilitation after primary treatment.
About the Chernihiv Medical Center of Modern Oncology of the Chernihiv Regional Council
Chernihiv Medical Center of Modern Oncology is a leading institution that provides highly specialized care to patients with oncological and onco-hematological pathologies. The Center provides all types of diagnosis and treatment (surgical treatment, chemotherapy, radiation therapy).
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2021, the Group employed around 100,000 people and had sales of 44.1 billion euros. R&D expenses before special items amounted to 5.3 billion euros. For more information, go to www.bayer.com.
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.